Recro Pharma, Inc. Insider Trading for April 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Recro Pharma, Inc. for April 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Miller James Charles | Director | Grant | A | 0.00 | 26,923 | 0 | 26,923 | 0 to 26.9 K |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Weisman Wayne | Director | Grant | A | 0.00 | 26,923 | 0 | 84,982 | 58.1 K to 85 K (+46.37 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Reasons Bryan M. | Director | Grant | A | 0.00 | 26,923 | 0 | 67,429 | 40.5 K to 67.4 K (+66.47 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Grant | A | 0.00 | 26,923 | 0 | 226,574 | 199.7 K to 226.6 K (+13.49 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | CHURCHILL WINSTON J | Director | Grant | A | 0.00 | 26,923 | 0 | 77,982 | 51.1 K to 78 K (+52.73 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Berelowitz Michael | Director | Grant | A | 0.00 | 26,923 | 0 | 76,546 | 49.6 K to 76.5 K (+54.26 %) |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Ashton William | Director | Option Exercise | A | 1.71 | 38,012 | 65,001 | 38,012 | |
| Apr 22 2021 | REPH | Recro Pharma, Inc. | Ashton William | Director | Grant | A | 0.00 | 26,923 | 0 | 80,280 | 53.4 K to 80.3 K (+50.46 %) |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Apr 15 2021 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | Director | Option Exercise | A | 2.93 | 20,000 | 58,600 | 20,000 | |
| Apr 12 2021 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Payment of Exercise | F | 3.24 | 5,172 | 16,757 | 376,564 | 381.7 K to 376.6 K (-1.35 %) |